Min Shen
About Min Shen
Min Shen is a Group Leader in Cheminformatics at the National Institutes of Health, with a strong background in pharmaceutical sciences and computational chemistry. He has over 18 years of experience in drug discovery across various therapeutic areas and possesses expertise in structure and ligand-based drug design techniques.
Work at National Institutes of Health
Min Shen has served as Group Leader of Cheminformatics at the National Institutes of Health (NIH) since 2008. In this role, he leads research initiatives focused on drug discovery and development. His work involves applying cheminformatics methodologies to support various therapeutic areas, enhancing the NIH's capabilities in pharmaceutical research. Shen's position at NIH has allowed him to contribute to significant advancements in the field.
Education and Expertise
Min Shen possesses a cross-disciplinary educational background. He earned his Bachelor's degree in Pharmaceutical Sciences from Peking University Health Science Center. He furthered his studies at the Chinese Academy of Sciences, where he obtained a Master's degree in Computational Chemistry. Shen completed his PhD in Computational Chemistry at the University of North Carolina at Chapel Hill from 1999 to 2003. His educational foundation supports his expertise in structure and ligand-based drug design techniques, including docking, homology modeling, QSAR/QSPR, and pharmacophore modeling.
Background
Min Shen has a diverse professional background in the pharmaceutical industry. He began his career as a Computational Chemist at Eli Lilly and Company from 2002 to 2003. Following this role, he worked as a Research Scientist at Lexicon Pharmaceuticals from 2004 to 2008. His experiences in these positions contributed to his extensive knowledge in drug discovery and development across various therapeutic areas.
Achievements in Drug Discovery
Throughout his 18-year career, Min Shen has gained significant experience in rational drug design, high-throughput screening, and drug repurposing. His involvement in drug discovery projects spans multiple therapeutic areas, including oncology, central nervous system (CNS) disorders, ophthalmology, inflammatory diseases, and metabolic diseases. This breadth of experience underscores his contributions to advancing pharmaceutical research and development.